Tech Company Financing Transactions
T3D Therapeutics Funding Round
T3D Therapeutics, based in Research Triangle Park, raised $15 million from National Institutes of Health.
Transaction Overview
Company Name
Announced On
11/5/2019
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to begin the PIONEER Study of T3D-959, a novel, metabolic-focused AD drug treatment.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
68 T.W. Alexander Dr. PO Box 13628
Research Triangle Park, NC 27709
USA
Research Triangle Park, NC 27709
USA
Phone
Website
Email Address
Overview
T3D Therapeutics, Inc. was founded in 2013 with a daunting mission -- to challenge the prevailing thinking over the last two decades in the development of solutions to effectively treat Alzheimer's disease. Our mission is to develop a ground-breaking, disease-modifying, new drug for the treatment of Alzheimer's disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Didsbury
Chief Medical Officer
Warren Strittmatter
Chief Scientific Officer
Stan Chamberlain
Browse more venture capital transactions:
Prev: 11/5/2019: C3 Industries venture capital transaction
Next: 11/5/2019: Kover.ai venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs